Managing itch associated with atopic dermatitis is a critical intervention to patient quality of life. Casey Butrus, PharmD: Dr Cameron, what’s the typical onset of action when you’re looking at a ...

Please provide your email address to receive an email when new articles are posted on . Ruxolitinib-treated patients achieved greater differences from baseline in itch intensity vs. vehicle. More ...

While other triggers are more likely to bring on an atopic dermatitis flare, Megan Rogge, MD, of UT Health in Houston talks about when to consider food allergies and recommend an elimination diet.

Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...

Please provide your email address to receive an email when new articles are posted on . Roflumilast cream 0.15% showed rapid itch reduction within 24 hours of first application. More than 40% of ...

How do dermatologists diagnose atopic dermatitis? To diagnose atopic dermatitis, also called eczema, a board-certified dermatologist carefully examines your (or your child's) skin and asks questions. ...

Shawn Kwatra, MD, FAAD, physician scientist at the University of Maryland Medical System, presented data at the American Academy of Dermatology 2025 annual conference on the rapid efficacy of topical ...

STAMFORD, Conn., March 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...

Topical ruxolitinib appears to quickly relieve itch in Black patients with atopic dermatitis (AD), an industry-sponsored analysis of pooled data from two studies suggests. "Ruxolitinib cream ...

Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements ...

A Bayesian network meta-analysis comparing four oral JAK inhibitors-upadacitinib, abrocitinib, baricitinib, and ivarmacitinib ...

Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab’s fast onset of ...